Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 8/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 2/20 | 0.41 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | MAPKAPK3 | Q16644 | 3/20 | 0.39 |
| ▸ | MAPK6 | Q16659 | 3/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.39 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22685979 | 0.88 | TNKS (0.49) | FGFR1FGFR2TNKSCCNCCDK8 | |
| SCHEMBL22685984 | 0.88 | MKNK1 (0.45) | FGFR1FGFR2TNKSCCNCCDK8 | |
| SCHEMBL22685937 | 0.88 | TNKS (0.48) | FGFR1FGFR2TNKSCCNCCDK8 | |
| SCHEMBL22685994 | 0.88 | JAK2 (0.45) | IDH1TNKSCCNCCDK8PIM1 | |
| SCHEMBL22708149 | 0.84 | IDH1 (0.51) | IDH1 | |
| SCHEMBL22708238 | 0.84 | CCNC (0.40) | FGFR1FGFR2TNKSCCNCCDK8 | |
| SCHEMBL22685952 | 0.83 | ITK (0.49) | IDH1PIM1 | |
| SCHEMBL22685983 | 0.83 | TNKS (0.47) | IDH1FGFR1FGFR2TNKSCCNC | |
| SCHEMBL22686016 | 0.82 | CCNC (0.43) | IDH1FGFR1FGFR2TNKSCCNC | |
| SCHEMBL22686000 | 0.82 | TTK (0.46) | FGFR1FGFR2TNKSCCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | NEW YORK UNIVERSITY (US) | 2022-07-26 | — | — | US | disclosed |
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | NEW YORK UNIVERSITY (US) | 2022-07-26 | — | — | US | disclosed |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | NEW YORK UNIVERSITY | 2020-11-26 | — | — | US | disclosed |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | NEW YORK UNIVERSITY | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | CAMKK2, CAMKK1, CAMK1 | IDH1 1375/4885FGFR1 3980/4885FGFR2 3718/4885 |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | CAMKK2, CAMKK1, CAMK1 | IDH1 1375/4885FGFR1 3980/4885FGFR2 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.